요약정보
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants.
- Resource Type
- Academic Journal
- Authors
- Messaoudene M; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France.; Mourikis TP; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Michels J; Gustave Roussy Cancer Campus (GRCC), Villejuif; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif.; Fu Y; Gustave Roussy Cancer Campus (GRCC), Villejuif.; Bonvalet M; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France.; Lacroix-Trikki M; Gustave Roussy Cancer Campus (GRCC), Villejuif; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.; Routy B; Gustave Roussy Cancer Campus (GRCC), Villejuif; Universitéde Montréal Hospital Research Centre (CRCHUM), Onco-Hematology Department, Montreal University Hospital Center (CHUM), Montréal, Québec, Canada.; Fluckiger A; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.; Rusakiewicz S; Center of Experimental Therapeutics (CET), Department of Oncology, Lausanne University Hospital, CHUV, Lausanne, Switzerland.; Roberti MP; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.; Cotteret S; Gustave Roussy Cancer Campus (GRCC), Villejuif.; Flament C; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.; Poirier-Colame V; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.; Jacquelot N; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif.; Ghiringhelli F; Georges-François Leclerc center, Medical Oncology, Dijon.; Caignard A; INSERM U1160, University Institute for Haematology, Saint Louis hospital, Paris.; Eggermont AMM; Gustave Roussy Cancer Campus (GRCC), Villejuif.; Kroemer G; Gustave Roussy Cancer Campus (GRCC), Villejuif; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus, Cordeliers Research Center, INSERM, U1138, Université Paris Descartes, Sorbonne Paris Cité; Université Pierre et Marie Curie; Pôle de Biologie, Européen Georges Pompidou Hospital, AP-HP, Paris.; Marabelle A; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Gustave Roussy Cancer Campus (GRCC), Drug Development Department (DITEP), Villejuif.; Arnedos M; Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif.; Vicier C; Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France.; Dogan S; Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif; Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France.; Jaulin F; Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif; Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France.; Sammut SJ; Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge.; Cope W; Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge; Cancer Research UK Cancer Centre and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Caldas C; Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge.; Delaloge S; Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif.; McGranahan N; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; André F; Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif; Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France.; Zitvogel L; Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France. Electronic address: Laurence.ZITVOGEL@gustaveroussy.fr.
- Source
- Publisher:
Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN:09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE - Subject
- Language
- English